Regulatory | ApexOnco - Clinical Trials news and analysis

“Top quality, fast and so easy to use”

Andrea Gnirke-Maier

Director New Product Planning

Morphosys

Click here for more information

9 November 2023

Another PI3K inhibitor bites the dust

Regulatory

2 November 2023

AstraZeneca's phase 3 TIGIT surprise

Regulatory

31 October 2023

Pfizer enters phase 3 with a CDK4 inhibitor

Regulatory Trial results

30 October 2023

Deciphera sets sights on a second marketed drug

Regulatory

30 October 2023

Loqtorzi becomes ninth US anti-PD-(L)1 drug

Regulatory

26 October 2023

AstraZeneca goes early with new datopotamab breast phase 3s

Regulatory

16 October 2023

Keytruda’s 25th EU green light

Regulatory

13 October 2023

Two BCL-2 inhibitors feature in phase 3 starts

Regulatory

11 October 2023

Sana shelves its in vivo Car-T

The once-hyped group’s most advanced hope is an allogeneic CD19 Car-T, where competition is fierce.

Regulatory

11 October 2023

Merck kicks off its first TROP2 phase 3

Subscribe to Regulatory

Another PI3K inhibitor bites the dust

AstraZeneca's phase 3 TIGIT surprise

Pfizer enters phase 3 with a CDK4 inhibitor

Deciphera sets sights on a second marketed drug

Loqtorzi becomes ninth US anti-PD-(L)1 drug

AstraZeneca goes early with new datopotamab breast phase 3s

Keytruda’s 25th EU green light

Two BCL-2 inhibitors feature in phase 3 starts

Sana shelves its in vivo Car-T

Merck kicks off its first TROP2 phase 3

Recent Quick take

Most Popular